Elim@CANSLIM ResearchIn Short
Liquidia's Q2 profit is a mirage: $74.7M net income inflated by a $40M legal settlement, while YUTREPIA growth slows to 31% from 44%. Stock fell 8.5% after hours—investors smell the litigation risk. The $1B by 2027 promise is a hope, not a plan. Read the full breakdown.
The Lede & The Real Story
Liquidia Corporation reported a headline-grabbing second quarter: net income of $74.7 million, revenue of $171.7 million, and adjusted EBITDA of $96.3 million. The stock, however, fell 8.49% in after-hours trading, closing at $72.10. That disconnect is the real story. Management’s scripted narrative—’YUTREPIA’s accelerating growth and profitability position it to exceed $1B in net revenue by 2027’—sounds triumphant, but the market’s reaction suggests investors see something else: a company whose earnings are flattered by one-time legal settlements, whose core product growth is decelerating, and whose future is hostage to a patent litigation that could erase its entire commercial franchise overnight.
The numbers tell a more nuanced tale. Revenue grew 29% quarter-over-quarter, from $132.9 million to $171.7 million, but that jump was not organic. A $40 million litigation settlement from United Therapeutics, disclosed in the quarterly report, padded the top line. Excluding that, YUTREPIA sales grew 31% sequentially—impressive, but down from the 44% growth reported in Q1. Adjusted EBITDA tripled in Q1, but in Q2 it grew just 18% sequentially. The market is not buying the $1 billion by 2027 promise, and the after-hours sell-off is the clearest signal that the ‘real story’ is about risk, not reward.
Subscribe to continue reading
Become a paid subscriber to get access to the rest of this post and other exclusive content.
